ARCHIVES

Assurances On Methods For Misconduct Reporting Required

This article is from The Cancer Letter archive.

Vol. 15 No. 46 | December 1, 1989

Download PDF Visit The Full Archive

Related Articles

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

March 29, 2013

In Turnaround, NCAB To Advise Screening Mammography for Women In Their Forties

March 28, 1997

FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer

April 26, 1996

O’Neill Recounts Private Meeting To Increase Cancer Appropriations

May 3, 1991

In Brief: FDA commissioner Kessler To Resign, Says His Goals Were Accomplished

November 29, 1996

Fountain Hearings Turn Up Some Responsible Criticism, some Not, Much Support for Program

June 24, 1977